The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NRIX | -16.93% | -58.87% | -16.27% | -13% |
| S&P | +13.99% | +77.08% | +12.11% | +114% |
Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $13.58M | 2.2% |
| Gross Profit | $8.95M | -0.4% |
| Gross Margin | 65.89% | -1.7% |
| Market Cap | $1.79B | 14.4% |
| Market Cap / Employee | $5.65M | 0.0% |
| Employees | 317 | 10.8% |
| Net Income | -$78,221.00K | -33.6% |
| EBITDA | -$78,464.00K | -30.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $246.96M | 124.5% |
| Accounts Receivable | $19.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $52.91M | 160.8% |
| Short Term Debt | $2.82M | -64.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.38% | -1.2% |
| Return On Invested Capital | -41.23% | -52.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$72,963.00K | -43.5% |
| Operating Free Cash Flow | -$67,832.00K | -39.1% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.22 | 1.69 | 1.59 | 3.65 | -7.24% |
| Price to Sales | 22.88 | 10.09 | 9.39 | 20.02 | -37.01% |
| Price to Tangible Book Value | 2.22 | 1.69 | 1.59 | 3.65 | -7.24% |
| Enterprise Value to EBITDA | -13.07 | -10.59 | -4.79 | -14.58 | -23.64% |
| Return on Equity | -64.2% | -50.7% | -65.4% | -49.6% | -6.74% |
| Total Debt | $26.62M | $51.93M | $56.49M | $55.73M | 96.90% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
